Kyverna Therapeutics, INC. (KYTX) — 8-K Filings

8-K Filings (17)

• Kyverna Therapeutics Files 8-K with Exhibits — Apr 22, 2026 Risk: low
  Kyverna Therapeutics, Inc. filed an 8-K on April 22, 2026, primarily for Regulation FD Disclosure and Financial Statements/Exhibits. The filing includes an exhi
• 8-K Filing — Apr 20, 2026
• Kyverna Therapeutics Files 8-K: Material Definitive Agreement — Dec 18, 2025 Risk: medium
  On December 17, 2025, Kyverna Therapeutics, Inc. entered into a material definitive agreement. The company, incorporated in Delaware with its principal executiv
• Kyverna Therapeutics Files 8-K — Dec 15, 2025 Risk: low
  Kyverna Therapeutics, Inc. filed an 8-K on December 15, 2025, reporting on Regulation FD Disclosure and Financial Statements and Exhibits. The filing details th
• 8-K Filing — Nov 3, 2025
• Kyverna Therapeutics Files 8-K — Oct 29, 2025 Risk: low
  Kyverna Therapeutics, Inc. filed an 8-K on October 29, 2025, reporting on Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not co
• Kyverna Therapeutics Reports Director/Officer Changes & Financials — Sep 25, 2025 Risk: medium
  Kyverna Therapeutics, Inc. filed an 8-K on September 25, 2025, reporting events as of September 19, 2025. The filing pertains to the departure and election of d
• Kyverna Therapeutics Files 8-K on Executive & Board Changes — Jun 30, 2025 Risk: medium
  Kyverna Therapeutics, Inc. filed an 8-K on June 30, 2025, reporting on the departure of directors or certain officers, election of directors, appointment of cer
• Kyverna Therapeutics Files 8-K on Shareholder Votes & Financials — Jun 3, 2025 Risk: low
  Kyverna Therapeutics, Inc. filed an 8-K on May 29, 2025, reporting on the submission of matters to a vote of security holders and financial statements. The comp
• Marinus to Acquire Kyverna Therapeutics for $550M — Jan 21, 2025 Risk: medium
  Kyverna Therapeutics, Inc. announced on January 21, 2025, that it has entered into a definitive agreement to be acquired by Marinus Pharmaceuticals, Inc. The tr
• Kyverna Therapeutics Files 8-K Report — Jan 13, 2025 Risk: low
  On January 13, 2025, Kyverna Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, as well as a Regulation FD
• Kyverna Therapeutics Appoints New CMO and CFO — Nov 26, 2024 Risk: low
  Kyverna Therapeutics, Inc. announced on November 26, 2024, that its Board of Directors appointed Dr. Michael J. Ybarra as Chief Medical Officer, effective Novem
• Kyverna Therapeutics Appoints New Chief Medical Officer — Oct 21, 2024 Risk: medium
  Kyverna Therapeutics, Inc. announced on October 21, 2024, that its Board of Directors has appointed Dr. Michael J. Ybarra as Chief Medical Officer, effective Oc
• Kyverna Therapeutics Appoints New Chief Medical Officer — Sep 16, 2024 Risk: medium
  Kyverna Therapeutics, Inc. announced on September 13, 2024, the appointment of Dr. Michael J. Ybarra as Chief Medical Officer. Dr. Ybarra brings extensive exper
• Kyverna Therapeutics Files 8-K — Jul 15, 2024 Risk: low
  On July 15, 2024, Kyverna Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Other Events, with no specific fina
• 8-K Filing — Jun 14, 2024
• Kyverna Opts Out of EGC Accounting Transition Period — Feb 12, 2024 Risk: low
  Kyverna Therapeutics, Inc. filed an 8-K on February 12, 2024, to report that it is an "emerging growth company" and has elected not to use the extended transiti

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX